These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 8525227)
1. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin]. Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227 [TBL] [Abstract][Full Text] [Related]
2. [Appropriate dosage of unfraction heparin and low molecular weight heparin in hemodialysis patients]. Xiao Q; Sun XF; Zhang D; Ma ZF; Wu MG; Wang H; Chen XM Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):187-91. PubMed ID: 20356555 [TBL] [Abstract][Full Text] [Related]
3. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio]. Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Camici M; Giordani R; Morelli E; Meriggioli M; Balestri PL; Barsotti G; Sagripanti A Minerva Med; 1998; 89(11-12):405-9. PubMed ID: 10212664 [TBL] [Abstract][Full Text] [Related]
5. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage]. Dieval J; Morinière P; Roussel B; Bayrou B; Fournier A; Delobel J J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482 [TBL] [Abstract][Full Text] [Related]
6. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Low CL; Bailie G; Morgan S; Eisele G Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524 [TBL] [Abstract][Full Text] [Related]
7. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis. Liu ZQ; Wang L Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628 [TBL] [Abstract][Full Text] [Related]
8. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597 [TBL] [Abstract][Full Text] [Related]
9. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347 [TBL] [Abstract][Full Text] [Related]
10. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs. Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748 [TBL] [Abstract][Full Text] [Related]
11. High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report. Rydzewska-Rosolowska A; Borawski J; Mysliwiec M Adv Med Sci; 2009; 54(2):199-202. PubMed ID: 19758969 [TBL] [Abstract][Full Text] [Related]
12. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation]. Kaizu K; Uriu K; Ikeda M Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886 [No Abstract] [Full Text] [Related]
13. The safety of heparins in end-stage renal disease. Sonawane S; Kasbekar N; Berns JS Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408 [TBL] [Abstract][Full Text] [Related]
14. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience]. Míka P; Behounek J; Skoták M; Nevsímal L Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102 [TBL] [Abstract][Full Text] [Related]
16. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses. Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943 [TBL] [Abstract][Full Text] [Related]
18. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?]. Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844 [TBL] [Abstract][Full Text] [Related]
19. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model. Ao PY; Hawthorne WJ; Coombs R; Fletcher JP Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369 [TBL] [Abstract][Full Text] [Related]
20. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin. Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]